Jing Zhao

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Sylvia Adams, P. Schmid, H. S. Rugo et al. · Annals of Oncology · 2018 · 795 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

Jeffrey L. Lennox, Edwin DeJesus, Adriano Lazzarin et al. · The Lancet · 2009 · 620 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

Joseph J. Eron, Jürgen K. Rockstroh, Jacques Reynes et al. · The Lancet Infectious Diseases · 2011 · 191 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +8

Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK

Jürgen K. Rockstroh, Jeffrey L. Lennox, Edwin DeJesus et al. · Clinical Infectious Diseases · 2011 · 165 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

Matthew L. Rizk, Yaming Hang, Wen‐Lin Luo et al. · Antimicrobial Agents and Chemotherapy · 2012 · 93 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +16